Grisnilimab (Anti-CD7 Antibody)

Grisnilimab, also known as WT1, is a IgG2a monoclonal antibody targeting CD7 (cluster of differentiation 7). Grisnilimab has been conjugated to aglycosylated ricin toxin A (RTA) to generate grisnilimab setaritox, also named as WT-1-RTA, and tested for the treatment of graft-versus-host-disease (GvHD). The CD7 antigen is a single-domain immunoglobulin superfamily molecule. It plays an essential role in T-cell interactions and T-cell/B-cell interaction during early lymphoid development. CD7 is highly expressed on malignant immature T cells and is generally absent on malignant mature T cells, such as CD4+ Sezary leukemia and HTLV-1+ adult T-cell leukemia cells. Interestingly, loss of CD7 antigen is observed in the subset of CD4+ memory T cells in some pathological conditions. Several studies indicate that the number of CD4+ CD7- T cells increase in chronic inflammation and various T-cell malignancies. CD7 is expressed in 95% of T-cell acute lymphoblastic leukemia (T-ALL) cases, which makes it an ideal target for T-ALL treatment. Grisnilimab is a anti-CD7 antibody, that has been conjugated to aglycosylated ricin toxin A (RTA) to generate grisnilimab setaritox, also named as WT-1-RTA, and tested for the treatment of graft-versus-host-disease (GvHD).